Versus Systems Inc. 8-K

What Happened

• On April 29, 2026, Nasdaq issued a deficiency letter to Versus Systems, Inc. after the company reported stockholders’ equity of $1,918,303 as of December 31, 2025, below the $2,500,000 minimum required by Nasdaq Listing Rule 5550(b)(1).
• The deficiency letter has no immediate effect on the listing, but Nasdaq gave Versus 45 days (until June 13, 2026) to submit a plan to regain compliance. If Nasdaq accepts the plan, the company may have until October 26, 2026 to cure the deficiency.
• As part of its plan, Versus entered into a Stock Purchase Agreement with ASPIS Cyber Technologies, Inc. (SPA dated April 15, 2026) to sell 1,513,128 shares at $1.1235 per share for total cash proceeds of $1,700,000, expected to close on or before May 14, 2026.

Key Details

• Nasdaq rule cited: Listing Rule 5550(b)(1) — $2,500,000 minimum stockholders’ equity.
• Versus reported stockholders’ equity of $1,918,303 in its Form 10-K for year ended Dec 31, 2025.
• SPA terms: $1,700,000 cash purchase, 1,513,128 shares, price per share $1.1235 (105% of the April 14, 2026 closing price).
• Deadlines: plan submission by June 13, 2026; possible compliance extension to October 26, 2026 if plan accepted.

Why It Matters

• For investors, the filing signals a near-term compliance issue with Nasdaq that could lead to delisting proceedings if not resolved. The deficiency letter itself does not immediately affect trading.
• The planned $1.7M stock sale, if closed, would provide a cash infusion likely intended to restore the required stockholders’ equity level and help avoid further Nasdaq action. That sale will also increase share count by 1,513,128 shares (potential dilution).
• Key near-term items to watch: whether the SPA closes as expected, the company’s submitted compliance plan, and whether Nasdaq accepts the plan and grants an extension.